A case of successful concurrent anti-cancer treatment in a patient who developed follicular lymphoma during treatment with afatinib for advanced lung adenocarcinoma

The present report describes the case of a 64-year-old woman with advanced lung adenocarcinoma expressing mutant epidermal growth factor receptor (EGFR). The patient developed follicular lymphoma during treatment with the EGFR-tyrosine kinase inhibitor afatinib. Standard immunochemotherapy for folli...

Descripción completa

Detalles Bibliográficos
Autores principales: Masuhiro, Kentaro, Koh, Genju, Takata, So, Nasu, Shingo, Takada, Hiromune, Morita, Satomu, Tanaka, Ayako, Shiroyama, Takayuki, Morishita, Naoko, Suzuki, Hidekazu, Okamoto, Norio, Kawasumi, Hiromi, Konishi, Chihiro, Hirashima, Tomonori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6554495/
https://www.ncbi.nlm.nih.gov/pubmed/31194139
http://dx.doi.org/10.1016/j.rmcr.2019.100862
Descripción
Sumario:The present report describes the case of a 64-year-old woman with advanced lung adenocarcinoma expressing mutant epidermal growth factor receptor (EGFR). The patient developed follicular lymphoma during treatment with the EGFR-tyrosine kinase inhibitor afatinib. Standard immunochemotherapy for follicular lymphoma was introduced in addition to continuing treatment with afatinib for lung cancer. Immunochemotherapy was effective and improved the patient's performance status while afatinib controlled the progression of lung cancer. Our case study suggests that it is safe to introduce standard immunochemotherapy for patients who develop malignant lymphoma while continuing treatment with tyrosine kinase inhibitors for lung adenocarcinoma expressing mutant EGFR.

Ejemplares similares